The kinetics of soluble and particulate antigen trafficking in the afferent lymph, and its modulation by aluminum-based adjuvant

Vaccine

Volumn 28, Issue 40, 2010, Pages 6597-6602

  de Veer, Michael ^a   Kemp, Joanna ^a   Chatelier, Josh ^a   Elhay, Martin J ^b   Meeusen, Els N T ^a  

^a MONASH UNIVERSITY   (Australia)

^b PFIZER INC   (United States)

Author keywords

Adjuvant; Dendritic cells; Lymph; Neutrophils

Indexed keywords

ALUMINUM HYDROXIDE; ANTIGEN; IMMUNOLOGICAL ADJUVANT; REHYDRAGEL; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ADJUVANTICITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN FUNCTION; ARTICLE; CANNULATION; CONTROLLED STUDY; DENDRITIC CELL; DRUG ANTIGENICITY; IMMUNIZATION; IMMUNOGENICITY; IMMUNOMODULATION; INJECTION SITE; LEUKOCYTE MIGRATION; LYMPH NODE; LYMPHATIC SYSTEM; MIGRATION INHIBITION; MONOCYTE; NEUTROPHIL COUNT; NONHUMAN; PRIORITY JOURNAL; SHEEP;

ADJUVANTS, IMMUNOLOGIC; ALUMINUM COMPOUNDS; ANIMALS; ANTIGENS; DENDRITIC CELLS; LYMPH; NEUTROPHILS; OVALBUMIN; SHEEP;

EID: 77956405814     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.07.056     Document Type: Article

References (25)

1. Lindblad E.B. Aluminium adjuvants--in retrospect and prospect. Vaccine 2004, 22:3658-3668.
2. Hem S.L., Hogenesch H. Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation. Expert Rev Vaccines 2007, 6:685-698.
3. WHO. Immunological adjuvants. World Health Organization technical report series no. 595; pp 6-8. Geneva: World Health Organization; 1976.
4. Jiang D., Morefield G.L., HogenEsch H., Hem S.L. Relationship of adsorption mechanism of antigens by aluminium-containing adjuvants to in vitro elution to interstitial fluid. Vaccine 2006, 24:1665-1669.
5. Seeber S.J., White J.L., Hem S.L. Solubilization of aluminium-containing adjuvants by constituents of interstitial fluid. J Parent Sci Technol 1991, 45:156-159.
6. Iyer S., HogenEsch H., Hem S.L. Relationship between the degree of antigen adsorption to aluminum hydroxide adjuvant in interstitial fluid and antibody production. Vaccine 2003, 21:1219-1223.
7. Iyer S., Robinett R.S., HogenEsch H., Hem S.L. Mechanism of adsorption of hepatitis B surface antigen by aluminum hydroxide adjuvant. Vaccine 2004, 22:1475-1479.
8. Hansen B., Belfast M., Soung G., Song L., Egan P.M., Capen R., et al. Effect of the strength of adsorption of hepatitis B surface antigen to aluminum hydroxide adjuvant on the immune response. Vaccine 2009, 27:888-892.
9. Kool M., Petrilli V., De Smedt T., Rolaz A., Hammad H., van Nimwegen M., et al. Cutting edge: alum adjuvant stimulates inflammatory dendritic cells through activation of the NALP3 inflammasome. J Immunol 2008, 181:3755-3759.
10. Morefield G.L., Sokolovska A., Jiang D., HogenEsch H., Robinson J.P., Hem S.L. Role of aluminium-containing adjuvants in antigen internalization by dendritic cells in vitro. Vaccine 2005, 23:1588-1595.
11. Eisenbarth S.C., Colegio O.R., O'Connor W., Sutterwala F.S., Flavell R.A. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 2008, 453:1122-1126.
12. Kool M., Soullie T., van Nimwegen M., Willart M.A., Muskens F., Jung S., et al. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J Exp Med 2008, 205:869-882.
13. Lambrecht B.N., Kool M., Willart M.A., Hammad H. Mechanism of action of clinically approved adjuvants. Curr Opin Immunol 2009, 21:23-29.
14. Franchi L., Nunez G. The Nlrp3 inflammasome is critical for aluminium hydroxide-mediated IL-1beta secretion but dispensable for adjuvant activity. Eur J Immunol 2008, 38:2085-2089.
15. Bujdoso R., Hopkins J., Dutia B.M., Young P., McConnell I. Characterization of sheep afferent lymph dendritic cells and their role in antigen carriage. J Exp Med 1989, 170:1285-1301.
16. Hall J.G. A method for collecting lymph from the prefemoral lymph node of unanaethetised sheep. Q J Exp Physiol 1967, 52:200-205.
17. Heimlich J.M., Reginer F.E., White J.L., Hem S.L. The in vitro displacement of absorbed model antigens from aluminium-containing adjuvants by interstitial proteins. Vaccine 1999, 17:2873-2881.
18. Haig D.M., Hopkins J., Miller H.R. Local immune responses in afferent and efferent lymph. Immunology 1999, 96:155-163.
19. Supersaxo A., Hein W.R., Steffen H. Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration. Pharm Res 1990, 7:167-169.
20. Noe S.M., Green M.A., HogenEsch H., Hem S.L. Mechanism of immunopotentiation by aluminum-containing adjuvants elucidated by the relationship between antigen retention at the inoculation site and the immune response. Vaccine 2000, 28:3588-3594.
21. Manolova V., Flace A., Bauer M., Schwarz K., Saudan P., Bachmann M.F. Nanoparticles target distinct dendritic cell populations according to their size. Eur J Immunol 2008, 38:1404-1413.
22. Abadie V., Badell E., Douillard P., Ensergueix D., Leenen P.J., Tanguy M., et al. Neutrophils rapidly migrate via lymphatics after Mycobacterium bovis BCG intradermal vaccination and shuttle live bacilli to the draining lymph nodes. Blood 2005, 106:1843-1850.
23. Bonneau M., Epardaud M., Payot F., Niborski V., Thoulouze M.I., Bernex F., et al. Migratory monocytes and granulocytes are major lymphatic carriers of Salmonella from tissue to draining lymph node. J Leukoc Biol 2006, 79:268-276.
24. Mosca F., Tritto E., Muzzi A., Monaci E., Bagnoli F., Iavarone C., et al. Molecular and cellular signatures of human vaccine adjuvants. Proc Natl Acad Sci U S A 2008, 105:10501-10506.
25. Itano A.A., McSorley S.J., Reinhardt R.L., Ehst B.D., Ingulli E., Rudensky A.Y., et al. Distinct dendritic cell populations sequentially present antigen to CD4 T cells and stimulate different aspects of cell-mediated immunity. Immunity 2003, 19:47-57.